On October 21, 2022 RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform, reported that the Company’s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27th at 1 p.m. ET (Press release, Renovorx, OCT 21, 2022, View Source [SID1234622275]). To register for the event please visit RenovoRx Fireside Chat Registration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the webinar, Mr. Bagai will discuss the company’s mission to become a leading provider in oncology therapy by disrupting standard of care (intravenous systemic chemotherapy) treatment of difficult-to-treat cancers, and how its unique RenovoTAMP therapy platform offers an innovative approach to delivering targeted chemotherapy to tumors. The goals of the RenovoTAMP therapy platform are to improve quality of life for patients living with difficult-to-treat cancer by reducing the debilitating side effects typical of standard of care chemotherapy treatment and to extend patient survival. Additionally, Mr. Bagai will review the Company’s pivotal Phase 3 TIGeR-PaC clinical trial which has its first interim analysis targeted for reporting in the fourth quarter of this year. The webinar is open to the public and participants will have an opportunity to ask questions during the Q&A portion of the webinar.

On October 21, 2022 Novocure (NASDAQ: NVCR) reported 11 poster presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting from Oct. 23 to Oct. 26 in San Antonio, Texas (Press release, NovoCure, OCT 21, 2022, View Source [SID1234622274]). Presentations include three investigator-led clinical studies, six pre-clinical studies and two dose-determining studies. Data reflect continued interest in Novocure’s proprietary TTFields platform within the radiation oncology community.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are encouraged by the data in GBM, ovarian cancer and non-small cell lung cancer, demonstrating the effects of Tumor Treating Fields in some of the most difficult to treat solid tumors where patients have limited treatment options"

TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has multiple mechanisms of action that can impact cancer cell division, disrupt cancer cell DNA damage repair, promote anti-cancer immunity, and interfere with cancer cell motility, making cancer cells more susceptible to different therapeutics.

New research includes positive results from a pre-clinical evaluation of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) with TTFields resulting in delays in tumor growth. Other pre-clinical research showed positive outcomes demonstrating that use of TTFields concurrently with other novel targeted therapies, such as PI3K and PARP inhibitors, has the potential for a therapeutic advantage. Clinical trials continue to investigate biomarkers predictive for survival in newly diagnosed glioblastoma (GBM).

"We are encouraged by the data in GBM, ovarian cancer and non-small cell lung cancer, demonstrating the effects of Tumor Treating Fields in some of the most difficult to treat solid tumors where patients have limited treatment options," said Frank Leonard, President of Novocure’s U.S. CNS (central nervous system) Cancers Franchise. "This research supports the growth of Novocure’s pipeline beyond GBM and shows the promise of our technology when used together with novel radiotherapies and targeted therapies."

The following will be presented at the ASTRO 2022 Annual Meeting:

Poster Presentations

Clinical Studies

(2149) Chemoradiation treatment with or without concurrent Tumor-Treating Fields (TTFields) in patients with newly diagnosed glioblastoma (GBM). Lead author and presenter: Louis Cappelli. 10:45 a.m. to 12 p.m. CDT Monday, Oct. 24.

(2150) Molecular markers impacting survival in patients receiving concurrent chemoradiation and Tumor-Treating Fields (TTF) in patients with newly diagnosed glioblastoma: secondary analysis of SPARE trial. Lead author and presenter: Louis Cappelli. 10:45 a.m. to 12 p.m. CDT Monday, Oct. 24.

(2152) A propensity-matched study to evaluate PTEN and TP53 mutations as predictive biomarkers of survival in newly diagnosed IDH-wildtype glioblastoma after Tumor Treating Fields. Lead author and presenter: James S. Cordova. 10:45 a.m. to 12 p.m. CDT Monday, Oct. 24.

Pre-Clinical Studies

(2154) Tumor Treating Fields (TTFields) enhance the efficacy of temozolomide and lomustine in glioblastoma cell lines. Lead author: Hila Fishman. Presenter: Moshe Giladi. 10:45 a.m. to 12 p.m. CDT Monday, Oct. 24.

(3164) Enhancing cancer cell membrane permeability by application of Tumor Treating Fields (TTFields). Lead author: Bella Koltun. Presenter: Moshe Giladi. 5 to 6 p.m. CDT Monday, Oct. 24.

(3165) Tumor Treating Fields (TTFields) delivery to macrophages promotes a pro-inflammatory phenotype. Lead author: Yiftah Barsheshet. Presenter: Moshe Giladi. 5 to 6 p.m. CDT Monday, Oct. 24.

(3169) Preclinical evaluation of Tumor Treating Fields Combined with Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR). Lead author: N.K. Karanam. Presenter: Michael D. Story. 5 to 6 p.m. CDT Monday, Oct. 24.

(2618) Tumor Treating Fields (TTFields) concomitant with PARP inhibitors for treatment of ovarian cancer cell lines. Lead author: Antonia Martinez-Conde. Presenter: Moshe Giladi. 5:15 to 6:15 p.m. CDT Tuesday, Oct. 25.

(2619) PI3K Inhibition sensitized cancerous cells to Tumor Treating Fields (TTFields). Lead author: Anat Klein-Goldberg. Presenter: Moshe Giladi. 5:15 to 6:15 p.m. CDT Tuesday, Oct. 25.

Dose Distribution Simulations

(3300) Examining array layouts for targeting a single lung with TTFields. Lead author and presenter: Ariel Naveh. 12:30 to 1:45 p.m. CDT Wednesday, Oct. 26.

(3233) Sensitivity of TTFields dose distribution in the lungs to the deviations in array placement. Lead author and presenter: Ariel Naveh. 12:30 to 1:45 p.m. CDT Wednesday, Oct. 26.

All poster presentations are located in Henry B. Gonzalez Convention Center, Exhibit Hall 1.

About Tumor Treating Fields

Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multi-mechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfieldstherapy.com.

On October 21, 2022 Elpiscience Biopharmaceuticals, Inc. ("Elpiscience"), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, reported it will have five poster presentations at the SITC (Free SITC Whitepaper) 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12 (Press release, Elpiscience, OCT 21, 2022, View Source [SID1234622273]). The posters will highlight studies on five innovative molecules including anti-SIRPα monoclonal antibody ES004, anti-LAG3 monoclonal antibody ES005, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and PD-L1/SIRPα bispecific macrophage engager ES019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentations:

1.Title: Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity
Abstract No.: 793
Date and time: 11/10/2022, 9:00 am – 9:00 pm (EST)

2.Title: Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity
Abstract No.: 1211
Date and time: 11/10/2022, 9:00 am – 9:00 pm (EST)

3.Title: SIGLEC15 induces monocyte apoptosis and an SIGLEC15 antibody ES012 reverses myeloid cells driven immunosuppression
Abstract No.: 1401
Date and time: 11/10/2022, 9:00 am – 9:00 pm (EST)

4.Title: ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models
Abstract No.: 426
Date and time: 11/11/2022, 9:00 am – 9:00 pm (EST)

5.Title: ES009, a LILRB2-specific blocking antibody, reprograms myeloid cells into pro-inflammation phenotype and potentiates T cell activation
Abstract No.: 1062
Date and time: 11/11/2022, 9:00 am – 9:00 pm (EST)

On October 21, 2022 Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, reported that introduced its new product, the MEVION S250-FIT Proton Therapy System (Press release, Mevion Medical Systems, OCT 21, 2022, View Source [SID1234622272]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Enabled by the world’s smallest self-shielded proton accelerator from Mevion, the MEVION S250-FIT will be the first and only full proton therapy system that can fit in an existing LINAC vault. The system will feature industry-leading HYPERSCAN Pencil Beam Scanning for Intensity Modulated Proton Therapy (IMPT), dual-energy large bore diagnostic CT at treatment position for IGRT and adaptive therapy, and FLASH research capabilities. It is also designed to support fast access to emerging technologies like ARC therapy.

Thanks to the compact size, the FIT system will further reduce the cost and complexity of proton therapy. As the name suggests, FIT will enable a Fast deployment of an Integrated design and bring the Transforming power of proton therapy to more cancer centers.

"The MEVION S250-FIT is a true quantum leap for proton accessibility. Fitting high-quality proton therapy inside a LINAC vault has always been a major goal in bringing the cost of proton closer to conventional X-ray, and as such, providing more access to this important therapy," said Jay Loeffler, MD, Chair Emeritus of Mass General Hospital and Co-Chair of Mevion’s Clinical and Technical Advisory Board.

"I have seen the clinical benefits of proton therapy for the past 20 years, especially for pediatric patients, and the idea that proton therapy could be accessible to all pediatric patients has always been my dream. I am so excited to hear of this innovation. This product could be a game changer," said Nancy Tarbell, MD, a world-renowned pediatric radiation oncologist, and CC Wang Professor emerita at Harvard Medical School and Mass General Hospital.

The FIT system will be developed in partnership with Leo Cancer Care, a medical device company based in Middleton, Wisconsin, with offices in Europe and North America. Leo Cancer Care is focused on bringing a "more human" approach to delivering radiation therapy and utilizes upright positioning to improve patient experience, clinical effectiveness, and access to radiotherapy.

"Mevion Medical Systems has a proven 18-year track record of technological innovation. We are excited to be disrupting the industry once again by shrinking proton therapy even more and by making this coveted technology much more accessible to patients who need it the most. Imagine the potential of bringing proton therapy to your cancer center within a year and having it fully integrated with other radiation modalities," said Tina Yu, PhD, CEO and President of Mevion Medical Systems. "Leo Cancer Care’s upright patient positioning system complements Mevion’s core technologies very well. They share our vision of democratizing proton therapy. We look forward to a long and rewarding partnership with Leo Cancer Care."

"Leo Cancer Care, like Mevion, has been focusing on the patient experience. Together, Leo and Mevion agreed we wanted to take proton therapy where we never thought it could go, and together we will be achieving what was once thought impossible. In working with Mevion, we will be able to scale down proton therapy in size and cost so that it can be within reach of patients who will benefit from it most," said proton therapy champion and veteran entrepreneur Rock Mackie, PhD, Board Chairman and Co-Founder of Leo Cancer Care.

Mevion will officially debut the MEVION S250-FIT Proton Therapy System at ASTRO’s 64th Annual Meeting in San Antonio, TX. Attendees are invited to join the unveiling at Mevion’s booth 566 at 2 PM CDT on October 23 and learn more about the system throughout the exhibition from October 23 – 25.

*The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.

On October 21, 2022 NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome to address disease at the base level using a new class of precision genetic medicines, reported a research agreement with a Top 10 Global Healthcare company ("Healthcare Company") (based on 2021 revenues) (Press release, NeuBase Therapeutics, OCT 21, 2022, View Source [SID1234622271]). For this research, the Healthcare Company will evaluate NeuBase’s PATrOL technology for three monogenic genetic diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NeuBase’s PATrOL platform is a PNA-based technology designed to address disease at the root of causality to help patients with rare and common diseases by editing, upregulating, or downregulating gene function. PATrOL gene editing is differentiated in that it does not require bacterial enzymes (e.g., CRISPR-Cas9), which potentially increases fidelity and reduces immunogenicity to provide a safer solution to patients for in vivo gene editing.

"Our PATrOL technology enables us to create a series of peptide nucleic acids (PNAs) designed to target a genetic mutation and recruit the cell’s own high fidelity nucleic acid repair machinery to resolve the mutation," stated Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase. "We look forward to working with our Healthcare Company partner to explore our novel gene editing technology for several genetic diseases."

Under the terms of the agreement, NeuBase and the Healthcare Company will collaborate on the evaluation of drug candidates for three undisclosed indications. The Healthcare Company will have the exclusive opportunity, subject to certain terms and conditions, to license and develop the drug candidates created under this research evaluation agreement.